World J Gastroenterol. 2010 Sep 21;16(35):4374-6. doi: 10.3748/wjg.v16.i35.4374.
Esophageal gastrointestinal stromal tumors (GISTs) are extremely uncommon, representing approximately 5% of GISTs with the majority of esophageal GISTs occurring at the esophagogastric junction (EGJ). The treatment options available for these GISTs are fairly controversial. Many different options are nowadays at our disposal. From surgery to the target therapies we have the possibility to treat the majority of GISTs, including those which are defined as unresectable. The EGJ GISTs represent a stimulating challenge for the surgeon. The anatomical location increases the possibility of post-operative complications. As the role of negative margins in GIST surgery is still controversial and the efficacy of target therapy has been demonstrated, why not treat EGJ GISTs with enucleation and, where indicated, adjuvant target therapy?
食管胃肠道间质瘤(GIST)极为罕见,约占 GIST 的 5%,大多数食管 GIST 发生在食管胃交界处(EGJ)。这些 GIST 的治疗选择存在相当大的争议。如今,我们有许多不同的选择。从手术到靶向治疗,我们有可能治疗大多数 GIST,包括那些被定义为不可切除的 GIST。EGJ GIST 对外科医生来说是一个具有挑战性的挑战。解剖位置增加了术后并发症的可能性。由于 GIST 手术中阴性切缘的作用仍存在争议,且靶向治疗的疗效已得到证实,那么为什么不采用剜除术治疗 EGJ GIST,并在必要时辅助靶向治疗呢?